Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Public policy

1508MO - Rationalizing the use of off-label drugs (OLD) within a special medication (ME) program for cancer patients (pt): The Catalan Institute of Oncology (ICO) prognostic score (ICO MEscore)


18 Sep 2021


Mini oral session - Public policy


Lucia Notario Rincon


Annals of Oncology (2021) 32 (suppl_5): S1102-S1110. 10.1016/annonc/annonc711


L. Notario Rincon1, C. Hierro1, A. Esteve1, S. Fontanals2, A. González3, E. Loureiro4, C. Sun1, M. Margelí1, T. Moran1, A. Font1, J.L. Manzano1, C. Balaña1, V. Quiroga1, N. Quer5, C. Ibañez6, J. Martínez-Benavides2, J. Brunet7, A. Clopes2, R. Mesia1

Author affiliations

  • 1 Medical Oncology Department, Catalan Institute Of Oncology (ICO) Badalona, 08916 - Barcelona/ES
  • 2 Oncology Pharmacy Department,, Catalan Institute of Oncology (ICO) Hospitalet, 08041 - Hospitalet/ES
  • 3 Badalona-applied Research Group In Oncology (b-argo), Germans Trias I Pujol Research Institute (IGTP), Badalona, 08041 - Barcelona/ES
  • 4 Information Technology Department (it), Catalan Institute of Oncology (ICO) Hospitalet, 08041 - Hospitalet/ES
  • 5 Oncology Pharmacy Department,, Catalan Institute Of Oncology (ICO) Girona, 08041 - Girona/ES
  • 6 Oncology Pharmacy Department,, Catalan Institute of Oncology (ICO) Badalona, 08041 - Badalona/ES
  • 7 Medical Oncology Department, Catalan Institute Of Oncology (ICO) Girona, 08916 - Girona/ES


Login to access the resources on OncologyPRO.

Abstract 1508MO


Molecularly targeted agents (MTA) and immunotherapies (IO) are approved for cancer pt. OLD can be used before the upcoming approval and in different scenarios or conditions from those reflected in regulatory summary approvals. ME programs allow pt to receive OLD. We aimed to improve ME pt selection by developing a prognostic score (ICO MEscore) that included clinic-analytical (CA) variables readily available in real practice.


Retrospective cohort of metastatic solid tumor pt treated with ME MTA/IO between Jan’11-Dec’19. A multivariate Cox regression model was fitted to predict the risk of death. The Akaike information criterion was considered in a backward selection method. ICO MEscore was derived from a final prognostic model and was categorized using the nomogram and prognostic scores resulting in similar Kaplan-Meier curves.


In total, 441 out of 541 (82%) cases treated with MTA (67%) or IO (33%) had available CA data. Most pt presented ECOG <2 (87%) and had received <3 previous lines (83%). Most frequent subtypes were thoracic (38%) and breast (19%) cancers, and 39% of all tumors harbored actionable oncogenic drivers. Overall, median overall survival (mOS) was 17.7 months (m) (95% CI 14-23). The final multivariate prognostic model included 8 risk factors: ECOG >=1, Body Mass Index <25, non-breast/thoracic tumors, hemoglobin <10.5 g/dL, neutrophil-to-lymphocyte ratio >3, platelet-to-lymphocyte ratio <150, >=2 sites of metastases and >=3 previous lines. Four prognostic groups were defined: low risk (LR) mOS 41.5 m (95% CI 35-NR), intermediate-low risk (ILR) mOS 18.1 m (95% CI 13.3-24), intermediate-high risk (IHR) mOS 7 m (95% CI 5.6-9.4) and high risk (HR) mOS 1.5 m (95% CI 1.2-4.2)(log rank test, p<0.001). 1-year OS rates were LR 80%, ILR 60% and IHR 36%, whereas there were no alive pt at 1-year in the HR group.


ICO MEscore is the first prognostic index under development for ME pt selection and our results suggest that could serve to identify HR pt with dismal prognosis. Further validation is warranted to confirm its applicability to rationalize ME decision-making.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.